ASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month …
Asparlas: Package Insert / Prescribing Info - Drugs.com
2024年10月13日 · ASPARLAS is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in …
FDA approves longer-acting calaspargase pegol-mknl for ALL
On December 20, 2018, the Food and Drug Administration approved calaspargase pegol-mknl (ASPARLAS, Servier Pharmaceuticals LLC), an asparagine specific enzyme, as a component …
Asparlas Uses, Side Effects & Warnings - Drugs.com
2024年10月21日 · What is Asparlas? Asparlas is used to treat acute lymphoblastic leukemia in children and young adults from 1 month to 21 years old. Asparlas may also be used for …
Calaspargase pegol - Wikipedia
Calaspargase pegol, sold under the brand name Asparlas, is a medication for the treatment of acute lymphoblastic leukemia (ALL). It is approved in the United States as a component of a …
ASPARLAS- calaspargase pegol injection, solution - DailyMed
2024年10月8日 · ASPARLAS® (calaspargase pegol-mknl) injection, for ... 1.1 Acute Lymphoblastic Leukemia - ASPARLAS is indicated as a component of a multi-agent …
FDA批准治疗急性淋巴性白血病的新药Asparlas上市 - 搜狐
2018年12月27日 · Asparlas（calaspargase pegol-mknl）是一种天冬酰胺特异性酶，表示作为治疗急性淋巴细胞白血病的多药物化疗方案的一个组成部分。 Asparlas能够将天冬酰胺分解为天冬 …
Asparlas (Servier Pharmaceuticals LLC): FDA Package Insert
2024年10月8日 · ASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult …
Asparlas (Calaspargase Pegol-mknl Injection): Side Effects ... - RxList
ASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month …
Drug Trials Snapshots: ASPARLAS - FDA
What is the drug for? ASPARLAS is used in combination with other drugs for the treatment of acute lymphoblastic leukemia (ALL) in patients 1 month to 21 years old. ALL is a rapidly …
- 某些结果已被删除